Sanofi has returned to T-cell engager (TCE) territory via an agreement to pay $180 million in the near term for a phase ...
Gilead Sciences (GILD) on Monday said it would acquire privately held Ouro Medicines, a biotech company developing T cell engager therapies for autoimmune diseases. The agreement includes $1.675 ...
I f your doctor has recommended chimeric antigen receptor (CAR) T-cell immunotherapy for large B-cell lymphoma (LBCL), you’ve likely already tried several standard treatments, and the cancer did not ...
UCSF scientists found a precise way to turn on cancer-fighting immune cells inside the body. This more potent form of CAR-T ...
Data are beginning to provide a clearer picture of chimeric antigen receptor T-cell therapy’s benefits and risks in lupus, ...
CDR111, an experimental MS therapy designed to eliminate harmful B-cells, reached an early development milestone.
Gilead Sciences is paying $1.67 billion for a T-cell engager (TCE) company via a front-loaded deal that could also give new ...
Understanding the interplay between T cells and B cells is pivotal to delineating both protective immunity and the pathogenesis of autoimmune diseases. Central to this dynamic are specialised CD4⁺ T ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results